March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Results Update from Second Sight’s Argus® II Retinal Prosthesis Study
Author Affiliations & Notes
  • Mark S. Humayun
    Ophthalmology, Doheny Eye Institute - USC, Los Angeles, California
  • Lyndon da Cruz
    Moorfields Eye Hospital, London, United Kingdom
  • Gislin Dagnelie
    Lions Vision Research and Rehab Center, Johns Hopkins University, Baltimore, Maryland
  • Jose-Alain Sahel
    Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France
  • Paulo E. Stanga
    Manchester Royal Eye Hospital, Manchester, United Kingdom
  • Eugene Filley
    Retina Foundation of the Southwest, Dallas, Texas
  • Dean Eliott
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Jacque Duncan
    University of California, San Francisco School of Medicine, San Francisco, California
  • Robert J. Greenberg
    Second Sight Medical Products, Sylmar, California
  • Argus II Study Group
    Ophthalmology, Doheny Eye Institute - USC, Los Angeles, California
  • Footnotes
    Commercial Relationships  Mark S. Humayun, Replenish (I, C, P, R), Second Sight Medical Products (I, C, P, R); Lyndon da Cruz, Second Sight Medical Products (F); Gislin Dagnelie, Second Sight Medical Products (F); Jose-Alain Sahel, Second Sight Medical Products (F); Paulo E. Stanga, Second Sight Medical Products (F); Eugene Filley, Second Sight Medical Products (F); Dean Eliott, Second Sight Medical Products (F); Jacque Duncan, Second Sight Medical Products (F); Robert J. Greenberg, Second Sight Medical Products (I, E, P)
  • Footnotes
    Support  NIH 5R01EY012893-10
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6953. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mark S. Humayun, Lyndon da Cruz, Gislin Dagnelie, Jose-Alain Sahel, Paulo E. Stanga, Eugene Filley, Dean Eliott, Jacque Duncan, Robert J. Greenberg, Argus II Study Group; Results Update from Second Sight’s Argus® II Retinal Prosthesis Study. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6953.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To provide an update on performance outcomes in the Argus II Retinal Prosthesis Study.

Methods: : Subjects had bare light perception or worse vision due to retinitis pigmentosa. All subjects were implanted with a Second Sight Argus II implant ( NCT00407602). Visual function was evaluated by a grating visual acuity test as well as by assessing the ability to determine the direction of motion of a line and the location of a square on an LCD screen. Orientation and mobility (O&M) tests were also given, which involved following a line and finding a door.

Results: : As of December 1, 2011, 30 subjects have been implanted at 10 centers (in the main study). Subjects have been implanted an average of 3.2 ± 0.9 years (range of 1.2 - 4.5), and all have used or are using the System at home. The rate of adverse events, which was moderate to begin with, has been further decreased by approximately 2x in the second half of the subjects (i.e., last 15 subjects). As for implant stability, 28 out of 30 devices are intact and functioning - one device was explanted around 14 months post-implant; a second remains implanted but functions intermittently due to partial loss of the RF link that provides power and data to the array. Results on visual function tests with high-contract stimuli showed a hierarchy of function, progressing from the ability to locate an object, through the ability to detect the direction of motion, and finally to the ability to distinguish the orientation of black and white gratings. To date, the best grating visual acuity measurement was 1.8 logMAR (20/1260). Functional vision O&M tests demonstrate that subjects are significantly better at performing visual tasks with the System ON vs. OFF and that this effect is maintained during long-term follow-up (i.e. >3years).

Conclusions: : With over 95 cumulative patient-years of follow-up on 30 subjects, this is the largest study of a visual prosthesis to date. The results confirm previous reports on the ability of the Argus II prosthesis to provide visual function and functional vision over the long-term. The Argus II Retinal Prosthesis System has received CE Mark and is now commercially available in Europe. Higher resolution devices are in development.

Clinical Trial: : NCT00407602

Keywords: retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.